MedTrace Logo

Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery

NCT00808964 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-06-10

No results posted yet for this study

Summary

This is a Phase 2, multicenter, open-label, single-arm, sequential cohort study to be conducted in up to 30 subjects. The study will evaluate subjects undergoing primary, elective, off-pump CABG surgery with median sternotomy.

Conditions

Interventions

DRUG

NU172

NU172 administered IV bolus followed by continuous infusion during CABG surgery

Sponsors & Collaborators

  • ARCA Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicholas Smedira, M.D. · The Cleveland Clinic

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-06-30
Completion
2013-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808964 on ClinicalTrials.gov